Newsletter
| Promoter: | Small Cap Leader | Paying Party: | TSX Ventures LLC |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| MBRX | $20000 | 1879844 |
| Max Profit: 6.28 % | Gain at close: -0.49 % |
Our records indicate that xxxxxx@gmail.com requested to be added to SmallCapLeader.com on Jun. 3, 2015. Click Here To Unsubscribe
New Alert: Moleculin Biotech, Inc. (NASDAQ: MBRX)
http://www.moleculin.com/
Last Close: $8.37
Good Morning!
Moleculin Biotech, Inc.(MBRX) is our new biotech Nasdaq alert that has the potential to be a game changer. Moleculin(MBRX) recently completed their IPO and became a publicly traded company on the Nasdaq last Thursday(June 2nd, 2016).
MBRX is an early stage biotech company focused on the development of game changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center, the world’s largest cancer research facility headquartered within the world’s largest medical center.
Moleculin's(MBRX) lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of acute myeloid leukemia(AML). AML(Acute Myeloid Leukemia) is a lethal form of cancer that starts in the tissues that form blood and currently has only one first-line treatment option. Since there are no approved second-line therapies, if the patient fails first-line therapy, the chances of survival diminish greatly. Annamycin is a new hope for AML Patients.
Before we get deeper into MBRX's lead drug candidate, it is important to mention another company who offers a comparative product and was bought out by Jazz Pharmaceuticals for $1.5 billion last Tuesday. This company is Celator Pharmaceuticals(CPXX). After the acquisition, CPXX jumped 71% from $17.53 to $30.01 overnight. This is important because the main reason Jazz Pharmaceuticals acquired Celator was so it could get its hands on a drug called VYXEOS, which like Annamycin, is a treatment for acute myeloid leukemia (or AML). Back in March, CPXX gained over 400% after announcing positive results from the Phase 3 trial of VYXEOS. The median overall survival for patients treated with VYXEOS in the study was 9.56 months compared to 5.95 months for patients receiving 7+3, representing a 3.61 month improvement in favor of VYXEOS.
In a person who has developed AML, cancerous white blood cells are produced instead and cause the body’s circulatory system to fail. The first-line treatment for eradication of these cancerous cells is called “7+3 induction therapy”, which is a 50+ year old treatment that is estimated to only be effective for about 20% of the AML population. With VYXEOS, instead of the "other" 80% of the AML population dying in 6 months, the drug extends the survival time to 9.5 months. That's more than significant enough to likely make VYXEOS the standard of care over current induction therapies, and why Jazz wanted it. But, based on clinical trials so far, Annamycin already looks like it outperforms VYXEOS.
First, Annamycin has the advantage of being engineered to be non-cardiotoxic. Cardiotoxic refers to drugs that cause severe, permanent, and sometimes fatal damage to the heart. Already, in multiple clinical trials involving a total of 114 patients with different cancers, no patient expressed any signs of cardiotoxicity.
It’s important to note that cardiotoxicity is the number one dose limiting toxicity of currently approved Anthracyclines used in the treatment of AML patients. Because of Annamycin’s lack of cardiotoxicity, patients will be able to be treated without the fear of life-threatening heart damage. We believe Annamycin's lack of cardiotoxicity alone makes it a game changing new drug.
The second major advantage with Annamycin is that it is “invisible” to the body’s natural defense mechanisms. This allows it to not be recognized by the multidrug resistance pumps that plague current therapies.
One of the leading Anthracyclines is Doxorubicin, which is both cardiotoxic and vulnerable to multidrug resistance. You can watch an animation of how an Anthracylcline therapy actually works by clicking here.
What’s most impressive about Annamycin is that in the two most recent trials, Annamycin was able to generate significant activity with acute leukemia patients who would be considered part of the unlucky 80% or labeled as “untreatable".
Specifically, in the most recent trial, 30% of patients who had failed an average of five previous induction therapies of 7+3, responded to Annamycin well enough to qualify for a curative bone marrow transplant(which is the goal and can provide remission and save lives). Putting this in the context of the recent VYXEOS data, that would be the equivalent of getting an additional 24% of patients to qualify for a bone marrow transplant. And, at the same time, putting none of those patients at risk for heart damage.
The importance of this cannot be overstated, as we believe it makes Annamycin a potential game changer in the treatment of AML patients. Annamycin was given to a population of AML patients that didn’t respond to first-line therapy. On average, they received 5 induction therapies which ALL failed. Induction therapies like 7+3 are extremely aggressive treatments and take a significant toll on patients while trying to kill the cancer. At this point in the patient’s life, after 5 treatments, their bodies are beginning to fail them and death is near. Annamycin was able to take 30% of that near-death population and achieve a strong enough response to qualify for them for a curative bone marrow transplant. This is why the company believes there is truly new hope when it comes to the treatment of relapsed or refractory AML patients. Moleculin(MBRX) is strategically seeking approval as a "second line" therapy for important reasons.
This begins with recognizing that the FDA has the ability to grant accelerated approval on the basis of fewer and smaller clinical trials where a drug has the potential to fill a “significant unmet need".
Since there is NO approved second-line therapy for the treatment of relapsed and refractory AML patients and since an average of 80% of AML patients fail the first-line therapies, MBRX believes the unmet need for a second-line therapy is truly significant and that Annamycin could potentially fill that void. At the same time, since such a large majority of patients fail the first-line therapies, MBRX believes becoming the ONLY second-line therapy has potentially greater value than a first-line drug that is only successful in a minority of patients. Finally, if MBRX is able to get approved as a second-line therapy, they can then focus on generating the expanded data required to ultimately seek approval as a first-line therapy. MBRX also has two other drug development technologies. One involves a portfolio of small molecules focused on the treatment of melanoma, bladder cancer, pancreatic cancer, and stomach cancer. The other technology targets the treatment of Glioblastoma, which is the most common form of brain cancer.
We believe Moleculin(MBRX) is a promising early stage biotech company that is creating a solid portfolio of drug candidates. Read more about their lead drug candidate, Annamycin, by clicking here and get started on your research now.
Sincerely, Small Cap Leader
Reminder: If you decide to trade, remember to always use limit orders to control the price you are willing to pay.
Follow us on Twitter @SmallCapLeader for faster alerts and real time updates.
For Quicker Alerts Text Keyword "STOCKS" to 24587 to Receive our SMS Mobile Alerts!
You are receiving this email because you signed up to our free alert newsletter. If you want to unsubscribe, Click Here To Unsubscribe
Notice and Disclaimer-Please Read Carefully
We are engaged in the business of marketing and advertising companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. SmallCapLeader.com sponsored advertisements do not purport to provide an analysis of any company's financial position, operations or prospects and this is not to be construed as a recommendation by SmallCapLeader.com or an offer or solicitation to buy or sell any security. Neither the owner of SmallCapLeader.com nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit SmallCapLeader.com. SmallCapLeader.com makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors. Third parties and/or affiliates of SmallCapLeader.com may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. Smallcapleader.com has been compensated twenty thousand dollars by a third party(TSX Ventures LLC) for an investor awareness campaign regarding MBRX. Any compensation received constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.
Notice of Stock Price Movements and Volatility. Viewers of this newsletter should understand that trading activity and stock prices in many if not all cases tend to increase during the advertisement campaigns of the profiled companies and in many if not all cases tend to decrease thereafter. This tends to create above average volatility and price movements in the profiled company during the advertisement campaign that viewers should take into consideration at all times. Campaigns vary in length, and many are for short periods of time, typically less than a week. Some of the content in this release contains forward-looking information within the meaning of Section 27 A of the Securities Act of 1 993 and Section 21 E of the Securities Exchange Act of 1 934 including statements regarding expected continual growth of the profiled company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1 995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company's filings with the Securities and Exchange Commission. However, a company's past performance does not guarantee future results. Generally, the information regarding a company profiled is provided from public sources which we believe to be reliable but is not guaranteed by us as being accurate. Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission ("SEC") website www.sec.gov and the Financial Industry Regulatory Authority ("FINRA") website at www.finra.org. Any investment should be made only after consulting with a qualified investment advisor and reviewing the publicly available financial statement and other information about the company profiled and verifying that the investment is appropriate and suitable. SmallCapLeader.com makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained in this release or on our website. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and SmallCapLeader.com Network has no obligation to update any of the information provided. SmallCapLeader.com its owners, officers, directors, contractors and employees are not responsible for errors and omissions. From time to time certain content in our releases or website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our releases and website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled in our release or on our website may not have approved certain or any statements within the website. SmallCapLeader.com encourages viewers to supplement the information obtained from this release and our website with independent research and other professional advice. The content in this release is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. This release may provide hyperlinks to third party websites or access to third party content. SmallCapLeader.com, its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does SmallCapLeader.com control, endorse, or guarantee any content found in such sites. By accessing, viewing, or using the website or communications originating from this release, you agree that SmallCapLeader.com, its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that SmallCapLeader.com, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. SmallCapLeader.com uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. You agree to hold SmallCapLeader.com, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur arising out of the use of our website or the information in our press releases, profiles and opinions. You agree that use of our website is at your sole risk. SmallCapLeader.com disclaims all warranties of any kind, express or implied. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the SEC. The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or then FINRA at: www.finra.org . In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/investors/index.htm.
Questions regarding any information contained in this report may be sent to info@SmallCapLeader.com. To review Small Cap Leader’s website and its disclaimer, please visit www.SmallCapLeader.com.
|
PO Box 31431
Charleston SC 29417
USA
Unsubscribe | Change Subscriber Options
Charleston SC 29417
USA
Unsubscribe | Change Subscriber Options